Biogen (BIIB) Other Non-Current Liabilities (2009 - 2026)

Biogen has reported Other Non-Current Liabilities for 18 years, with the latest figure at $820.9 million in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 2.66% year-over-year to $820.9 million in Q2 2026; TTM through Jun 2026 was $820.9 million, a 2.66% increase from a year earlier, with the FY2025 full-year figure at $748.5 million, up 2.21% from the prior year.
• Other Non-Current Liabilities was $820.9 million for Q2 2026 at Biogen, up from $787.1 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $1.3 billion in Q1 2022, with the low at $556.7 million in Q2 2024.
• Average Other Non-Current Liabilities over 5 years is $851.1 million, with a median of $779.1 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities tumbled 37.58% in 2023, then jumped 43.63% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $944.2 million in 2022, then retreated by 17.27% to $781.1 million in 2023, then slipped by 6.25% to $732.3 million in 2024, then advanced by 2.21% to $748.5 million in 2025, then grew by 9.67% to $820.9 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $820.9 million (Q2 2026), $787.1 million (Q1 2026), and $748.5 million (Q4 2025), per Business Quant data.